Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

BACKGROUND: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety. METH...

Deskribapen osoa

Xehetasun bibliografikoak
Egile Nagusiak: Ascierto, Paolo Antonio, Del Vecchio, Michele, Mackiewicz, Andrzej, Robert, Caroline, Chiarion-Sileni, Vanna, Arance, Ana, Lebbé, Céleste, Svane, Inge Marie, McNeil, Catriona, Rutkowski, Piotr, Loquai, Carmen, Mortier, Laurent, Hamid, Omid, Bastholt, Lars, Dreno, Brigitte, Schadendorf, Dirk, Garbe, Claus, Nyakas, Marta, Grob, Jean-Jacques, Thomas, Luc, Liszkay, Gabriella, Smylie, Michael, Hoeller, Christoph, Ferraresi, Virginia, Grange, Florent, Gutzmer, Ralf, Pikiel, Joanna, Hosein, Fareeda, Simsek, Burcin, Maio, Michele
Formatua: Online Artikulua Texto
Hizkuntza:English
Argitaratua: BMJ Publishing Group 2020
Gaiak:
Clinical/Translational Cancer Immunotherapy
Sarrera elektronikoa:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279645/
https://www.ncbi.nlm.nih.gov/pubmed/32503946
http://dx.doi.org/10.1136/jitc-2019-000391

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7279645/
https://www.ncbi.nlm.nih.gov/pubmed/32503946
http://dx.doi.org/10.1136/jitc-2019-000391

Antzeko izenburuak